Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy

被引:210
|
作者
Rowin, Ethan J. [1 ]
Hausvater, Anais [1 ]
Link, Mark S. [1 ]
Abt, Patrick [1 ]
Gionfriddo, William [1 ]
Wang, Wendy [1 ]
Rastegar, Hassan [1 ]
Estes, N. A. Mark [1 ]
Maron, Martin S. [1 ]
Maron, Barry J. [1 ]
机构
[1] Tufts Med Ctr, HCM Inst, Div Cardiol, Boston, MA USA
关键词
AF ablation; atrial fibrillation; hypertrophic cardiomyopathy; maze procedure; ADVANCED HEART-FAILURE; LONG-TERM OUTCOMES; CATHETER ABLATION; NATURAL-HISTORY; TASK-FORCE; RISK; IMPACT; MANAGEMENT; STROKE; MORTALITY;
D O I
10.1161/CIRCULATIONAHA.117.029267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Atrial fibrillation (AF), the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), is capable of producing symptoms that impact quality of life and is associated with risk for embolic stroke. However, the influence of AF on clinical course and outcome in HCM remains incompletely resolved. METHODS: Records of 1558 consecutive patients followed at the Tufts Medical Center Hypertrophic Cardiomyopathy Institute for 4.8 +/- 3.4 years (from 2004 to 2014) were accessed. RESULTS: Of the 1558 patients with HCM, 304 (20%) had episodes of AF, of which 226 (74%) were confined to symptomatic paroxysmal AF (average, 5 +/- 5; range, 1 to >20), whereas 78 (26%) developed permanent AF, preceded by 7 +/- 6 paroxysmal AF episodes. At last evaluation, 277 patients (91%) are alive at 62 +/- 13 years of age, including 89% in New York Heart Association class I or II. No difference was found in outcome measures for patients with AF and age-and sex-matched patients with HCM without AF. Four percent of patients with AF died of HCM-related causes (n=11), with annual mortality 0.7%; mortality directly attributable to AF (thromboembolism without prophylactic anticoagulation) was 0.1% per year (n=2 patients). Patients were treated with antiarrhythmic drugs (most commonly amiodarone [n=103] or sotalol [n=78]) and AF catheter ablation (n=49) or the Maze procedure at surgical myectomy (n=72). Freedom from AF recurrence at 1 year was 44% for ablation patients and 75% with the Maze procedure (P<0.001). Embolic events were less common with anticoagulation prophylaxis (4/233, 2%) than without (9/66, 14%) (P<0.001). CONCLUSIONS: Transient symptomatic episodes of AF, often responsible for impaired quality of life, are unpredictable in frequency and timing, but amenable to effective contemporary treatments, and infrequently progress to permanent AF. AF is not a major contributor to heart failure morbidity or a cause of arrhythmic sudden death; when treated, it is associated with low disease-related mortality, no different than for patients without AF. AF is an uncommon primary cause of death in HCM virtually limited to embolic stroke, supporting a low threshold for initiating anticoagulation therapy.
引用
收藏
页码:2420 / +
页数:19
相关论文
共 50 条
  • [1] Letter by Wang and Zhao Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy"
    Wang, Lei
    Zhao, Yun-Tao
    [J]. CIRCULATION, 2018, 137 (23) : 2540 - 2540
  • [2] Letter by Zhang and Xu Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy"
    Zhang, Li
    Xu, Xiao-mao
    [J]. CIRCULATION, 2018, 137 (23) : 2539 - 2539
  • [3] Clinical Profile and Prognostic Significance of Atrial Fibrillation in Hypertrophic Cardiomyopathy
    Tian, Tao
    Wang, Yilu
    Sun, Kai
    Wang, Jizheng
    Zou, Yubao
    Zhang, Weili
    Bao, Jingru
    Zhu, Ling
    Shen, Hu
    Hui, Rutai
    Zhou, Xianliang
    Song, Lei
    [J]. CARDIOLOGY, 2013, 126 (04) : 258 - 264
  • [4] Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy"
    Rowin, Ethan J.
    Maron, Martin S.
    Maron, Barry J.
    [J]. CIRCULATION, 2018, 137 (23) : 2541 - 2542
  • [5] Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy
    Olivotto I.
    Maron B.J.
    Cecchi F.
    [J]. Current Cardiology Reports, 2001, 3 (2) : 141 - 146
  • [6] Clinical predictors and consequences of atrial fibrillation after surgical myectomy for obstructive hypertrophic cardiomyopathy
    Ommen, SR
    Thomson, HL
    Nishimura, RA
    Tajik, AJ
    Schaff, HV
    Danielson, GK
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02): : 242 - +
  • [7] Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy
    Olivotto, I
    Cecchi, F
    Casey, SA
    Dolara, A
    Traverse, JH
    Maron, BJ
    [J]. CIRCULATION, 2001, 104 (21) : 2517 - 2524
  • [8] Atrial Fibrillation in Hypertrophic Cardiomyopathy
    El-Battrawy, Ibrahim
    Borggrefe, Martin
    Akin, Ibrahim
    [J]. JACC-HEART FAILURE, 2018, 6 (09) : 807 - 807
  • [9] Atrial Fibrillation in Hypertrophic Cardiomyopathy
    Vaidya, Kaivan
    Semsarian, Christopher
    Chan, Kim H.
    [J]. HEART LUNG AND CIRCULATION, 2017, 26 (09): : 975 - 982
  • [10] Clinical implication of atrial fibrillation in patients with apical hypertrophic cardiomyopathy
    Lee, S. E.
    Park, J. K.
    Uhm, J. S.
    Kim, J. Y.
    Pak, H. N.
    Lee, M. H.
    Joung, B. Y.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 686 - 687